

# 1 Evaluating the performance of the WHO 2 international reference standard for osteoporosis 3 diagnosis in postmenopausal women of varied 4 polygenic score and race

5 Qing Wu, MD, ScD <sup>1,2,\*</sup>, Xiangxue Xiao, MSPH <sup>1,2</sup> and Yingke Xu, MSPH <sup>1,2</sup>

6 <sup>1</sup> Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, NV 89154, USA;

7 <sup>2</sup> Department of Environmental and Occupational Health, School of Public Health, University of Nevada  
8 Las Vegas, NV 89154, USA;

9 \* Correspondence: qing.wu@unlv.edu; Tel.: +01-702-895-1439

10 Received: date; Accepted: date; Published: date

11 **Abstract:** Background: Whether the bone mineral density (BMD) T-score performs differently in  
12 osteoporosis classification in women of different genetic profiling and race background remains  
13 unclear. Methods: The genomic data in the Women's Health Initiative study was analyzed (n=2,417).  
14 The polygenic score (PGS) was calculated from 63 BMD-associated single nucleotide  
15 polymorphisms (SNPs) for each participant. The World Health Organization's (WHO) definition of  
16 osteoporosis (BMD T-score $\leq$ -2.5) was used to estimate the cumulative incidence of fracture. Results:  
17 T-score classification significantly underestimated the risk of major osteoporotic fracture (MOF) in  
18 the WHI study. An enormous underestimation was observed in African American women (POR:  
19 0.52, 95% CI: 0.30-0.83) and in women with low PGS (predicted/observed ratio [POR]: 0.43, 95% CI:  
20 0.28-0.64). Compared to Caucasian women, African American, African Indian, and Hispanic women  
21 respectively had a 59%, 41%, and 55% lower hazard of MOF after the T-score was adjusted for. The  
22 results were similar when used for any fractures. Conclusions: Our study suggested the BMD T-  
23 score performance varies significantly by race in postmenopausal women.

24 **Keywords:** polygenic score (PGS); bone mineral density (BMD); single nucleotide polymorphism  
25 (SNP).

26

## 27 1. Introduction

28 Osteoporosis is a common, progressive systemic skeletal disease characterized by low bone  
29 mass and deteriorated bone tissue, resulting in an increase in bone fragility and susceptibility to  
30 fracture [1]. Osteoporosis-associated fractures often cause a significant increase in morbidity,  
31 mortality, and accompanying social and economic costs [2]. By estimation, about 50% of  
32 postmenopausal Caucasian women and 20% of Caucasian men in the US will suffer at least one  
33 fragility fracture after the age of 50 [3]. With life expectancy increasing universally, osteoporosis  
34 and fracture will become an ever-growing health problem worldwide [4].

35 Osteoporosis is a silent disease because bone loss occurs or bone tissue deteriorates without  
36 any symptoms [4]. Patients often are not aware that they have osteoporosis until a fracture occurs.  
37 Thus, correctly diagnosing osteoporosis and identifying individuals who will sustain osteoporotic  
38 fracture is critical for the prevention of devastating fracture outcomes in the aging population. As  
39 BMD is the single strongest predictor of primary osteoporotic fracture [5], clinical osteoporosis  
40 diagnosis is based on BMD measurements from dual-energy x-ray absorptiometry (DEXA)

41 ~~NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.~~  
42 osteoporosis as a femur neck BMD that lies  $\geq 2.5$  standard deviations below (T-score  $\leq -2.5$ ) the mean

43 value for young, healthy women [7]. This definition becomes the WHO international reference  
44 standard for osteoporosis diagnosis. However, the major limitation of this WHO reference  
45 standard is its low sensitivity; most fractures occur in individuals with a femur neck BMD T-score  
46  $>-2.5$ . Also, because many other risk factors, including age, female gender, and previous fracture,  
47 are associated with fracture risk independently of BMD, several predictive models have been  
48 developed to estimate fracture risk from these established risk factors. The Fracture Risk  
49 Assessment Tool (FRAX) is the most commonly used fracture risk assessment tool in the US [8].  
50 Although FRAX improves fracture prediction over the BMD T-score method alone, the predictive  
51 performance of both FRAX and WHO T-score method varies in different population cohorts [8,9]  
52 and with different conditions [10,11].

53 The original FRAX was developed from nine large cohorts and then validated in 11  
54 independent cohorts across the world [1]. The US FRAX was calibrated from the data of the  
55 Rochester Epidemiology Project [12], composed predominantly of Caucasians [13]. Further, the T-  
56 score was initially proposed only for postmenopausal Caucasian women [14,15]. Although both  
57 FRAX and T-score were adjusted subsequently for race and ethnicity, the methodology for the  
58 adjustment was not empirically based, thus rendering their performance for fracture prediction  
59 unreliable in minorities. Besides, neither FRAX nor T-score takes account of genetic components  
60 even though research has shown that hereditary factors are determinants of bone structure and are  
61 strongly associate with bone mass decrease, bone deterioration, and fragility fractures. With the  
62 development of advanced genomic technologies, numerous genetic loci related to fracture and  
63 BMD have been discovered in major genome-wide association studies (GWASs) and genome-wide  
64 meta-analyses. Both of these factors provide a unique opportunity to examine the performance of  
65 existing clinical fracture prediction approaches in groups with different genomic profiling.

66 Our previous study has examined the performance of FRAX in postmenopausal women by  
67 race and polygenic score, computed from fracture-associated SNPs discovered in the largest GWAS  
68 meta-analysis (under review). The T-score method ( $T\text{-score} \leq -2.5$ ) is the WHO international  
69 reference standard for osteoporosis diagnosis and has been endorsed by numerous professional  
70 societies, including the International Society of Clinical Densitometry (ISCD) [16], and widely used  
71 in clinical practice for osteoporosis diagnosis. However, the performance of the T-score method for  
72 osteoporosis classification in the U.S. minorities was rarely studied, and the T-score performance in  
73 osteoporosis classification with different genetic profiling has never been reported in the literature.  
74 Thus, this study aimed first to evaluate whether T-score performs differently in osteoporosis  
75 classification with different polygenic risk scores, and second to assess T-score performance in  
76 osteoporosis diagnosis by race in women. We also examined the extent to which the interaction of  
77 race and polygene scores impacts the T-score performance in osteoporosis classification and  
78 fracture prediction.

## 79 **2. Experimental Section**

### 80 *2.1. Data Source*

81 The Women's Health Initiative (WHI) study is a nationwide longitudinal study to examine the  
82 health of postmenopausal women aged 50-79 years who have no severe medical conditions at  
83 baseline [17]. Between 1993 and 1998, the WHI enrolled 161,809 women aged 50 to 79 years at 40  
84 clinical centers nationwide. The details of WHI recruitment and follow-up procedures have been  
85 described elsewhere [17]. Briefly, eligible women were enrolled in one or more randomized Clinical  
86 Trials (CT) or to an Observational Study (OS). Participants were followed up on by mail or  
87 telephone semiannually in CT and with questionnaires annually in the OS. The Institutional Review  
88 Boards at each participating institution approved the study protocols and participant consent forms  
89 [17].

90

## 91 2.2. *Participants*

92 The data used for the present study were de-identified and were acquired through the  
93 database of Genotype and Phenotype (dbGap) ([https://www.ncbi.nlm.nih.gov/projects/gap/cgi-](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3)  
94 [bin/study.cgi?study\\_id=phs000200.v12.p3](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3)) with the approval of the institutional review board at the  
95 University of Nevada, Las Vegas. The data included in this analysis were merged from four WHI  
96 sub-studies, WHI Genomics and Randomized Trials Network (GARNET), National Heart Lung,  
97 and Blood Institute (NHLBI), Population Architecture using Genomics and Epidemiology (PAGE),  
98 and Women's Health Initiative Memory Study (WHIMS). On baseline questionnaires, participants  
99 provided information on age, race/ethnicity, smoking, physical activity, and supplement use. The  
100 included subjects were genotyped using either the Affymetrix 6.0 array set (Affymetrix, Santa  
101 Clara, California) or the Illumina (Illumina, San Diego, California) platform. Participants who did  
102 not have BMD measurements were excluded from the analytic sample. In total, there were 2,417  
103 eligible participants from multiple ethnic backgrounds, with genotype data and adjudicated  
104 fracture outcomes available.

## 105 2.3. *BMD measurements*

106 BMD was measured for women using dual-energy X-ray absorptiometry (QDR 2000 or 2000+,  
107 or 4500 W; Hologic Inc, Bedford, MA, USA) at three participating US clinical centers (Birmingham,  
108 AL; Pittsburgh, PA; and Tucson/Phoenix, AZ). Certified technicians using standard protocols  
109 measured BMD of the total hip, lumbar spine (L2-L4), and total body. Baseline BMD measurements  
110 were employed to classify participants in order to determine if they have osteoporosis at baseline in  
111 this study. Standard quality assurance protocols for positioning and analysis, routine hip and spine  
112 phantoms, and review of a randomly selected sample were employed. Changes of hardware and  
113 software were centralized and calibrated, and calibration phantoms across instruments and clinical  
114 sites were in close agreement, with inter-scanner variability <1.5% for the spine, <4.8% for the hip,  
115 and <1.7% for linearity [18]. BMD T-scores were calculated for each individual by using the young  
116 adult, normal Caucasian women reference databases. Osteoporosis was defined as a BMD that lies  
117 2.5 standard deviations or less below the average value for young, healthy women [19].

## 118 2.4. *Outcomes: Incident Fractures*

119 In this study, any fractures were defined as all fractures except those of fingers, toes, ribs,  
120 sternum (or chest), skull (or face), and cervical vertebrae. Major osteoporotic fracture (MOF) was  
121 defined as a composite of hip, humerus, forearm, and clinical vertebral fractures. The study  
122 participants were followed for 19 years, from the inception of WHI initial study to the end of the  
123 WHI extension study II, to ensure a sufficiently long follow-up duration to capture enough events.  
124 The follow-up period was computed from the date of the enrollment (OS) or randomization (CT) to  
125 the time of the first fracture or the time of death. Self-reported fracture outcomes were identified  
126 annually in OS and semiannually in CT by questionnaires. All fractures in the CT and hip fractures  
127 in the OS were adjudicated by using radiology reports. Hip fractures were adjudicated centrally or  
128 locally using the same criteria. The agreement between central and local adjudication was 96% for  
129 hip fractures [20]. Other types of fractures were adjudicated locally at the clinical centers which  
130 were not designed for BMD measurements in the WHI study [17].

## 131 2.5. *Genotyping*

132 Blood samples were genotyped using genomic DNA for WHI participants. Genomic data of  
133 WHI were acquired through dbGap. Genotype imputation was conducted at the Sanger Imputation  
134 Server to impute variants that were missing, un-typed, or poorly captured in the original data. The

135 Haplotype Reference Consortium (HRC) reference panel and Positional Burrows-Wheeler  
136 Transform (PBWT) imputation algorithm were employed for genotype imputation. All 63 fracture-  
137 associated SNPs reported by Estrada et al. [21] were successfully imputed. The imputation quality  
138 was high, with  $R^2 = 0.99$ .

### 139 2.6. Polygenic score

140 Genetic risk for decreased BMD was quantified using a standardized metric described in detail  
141 by Estrada et al. [21]. Briefly, this metric allows the composite assessment of genetic risk for  
142 complex traits by summarizing the genetic predisposition. Based on 63 femoral neck BMD-  
143 associated SNPs discovered in the largest genome-wide meta-analysis [21], polygenic score was  
144 computed as  $PGS = \sum (x_i * b_i)$ ; where  $x_i$  are individual's genotype (0, 1, 2) for SNP  $i$ , and  $b_i$  are  
145 the effect size of this SNP. Linkage disequilibrium (LD) pruning was executed in advance to  
146 remove possible LD that existed between SNPs. None of the 63 SNPs were deleted after pruning. To  
147 demonstrate if the performance of the WHO international reference standard for osteoporosis  
148 diagnosis varied by PGS, eligible WHI participants were divided into three PGS groups using  
149 distribution of 25%, 50%, and 25%.

### 150 2.7. Statistical Analysis

151 Demographic and baseline clinical characteristics are presented as mean  $\pm$  SD for continuous  
152 variables or frequencies (%) for categorical variables. Differences between the individuals with and  
153 without a fracture were examined by using Student's t-test for continuous variables and by using chi-  
154 square tests or Fisher's exact test (when numbers were small) for categorical variables, respectively.  
155 The observed cumulative incidence of fracture from the start of WHI to the end of WHI extended II  
156 was assessed by race and PGS groups. The cumulative incidence function (CIF) was applied to derive  
157 the observed fracture probability for MOF and any fracture with competing mortality risk accounted  
158 for. The ratio between T-score predicted fracture incidence and observed fracture incidence (POR),  
159 with the corresponding 95% CI, was calculated for each subgroup.

160 To assess the performance of the T-score method in classifying osteoporosis in different  
161 subgroups, the false-positive rate and the false-negative rate was calculated for each PGS and race  
162 group. Multivariate Cox proportional hazard model was further employed to assess the effect of PGS  
163 and race on the outcome of MOF or any fracture within 19 years, with baseline T-score controlled for.  
164 T-score diagnosis was treated as a binary categorical variable in the Cox proportional hazard model.  
165 A sensitivity analysis was conducted on a small sample ( $N=1,775$ ) in which participants who had  
166 previous fractures were excluded. Statistical analyses were performed using the SAS 9.4 (SAS  
167 Institute, Inc., Cary, NC, USA).

## 168 169 3. Results

### 170 3.1. Baseline characteristics

171 The study included a total of 2,417 women for analysis. During the 19-year follow-up period,  
172 634 (26.23%) women died, and 289 (11.96%) women sustained at least one fracture at any skeletal  
173 site during the follow-up. **Table 1** compares the baseline characteristics of women with and without  
174 any fracture during the follow-up. Women who sustained a fracture were older ( $p < 0.001$ ), had  
175 lower body mass index (BMI), higher prevalence of prior fractures ( $p < 0.001$ ), and more hip fractures  
176 in their family history ( $p = 0.002$ ). T-score was significantly lower in women with a fracture incidence  
177 ( $p < 0.0001$ ). PGS was not significantly different between women who sustained a fracture and women  
178 who did not ( $p = 0.81$ ).

179

180 **Table 1.** Baseline Characteristics of 2,417 women with and without any subsequent fracture during 19 years of  
181 follow-up

	Subjects with any fracture event (n =289)	Subjects without any fracture event (n =2,128)	p value
Age (year), mean (SD)	65.90 ± 7.33	62.38 ± 7.63	<b>&lt;.0001</b>
Weight (kg), mean (SD)	76.15 ± 15.59	77.56 ± 16.53	0.23
Height (cm), mean (SD)	161.61 ± 5.79	160.95 ± 6.01	0.12
Body mass index (kg/m <sup>2</sup> ), mean (SD)	29.16 ± 5.58	29.89 ± 5.97	0.08
Smoking, No. (%)			
Never	166 ± 59.29	1191 ± 56.74	
Past	100 ± 35.71	692 ± 32.397	<b>0.02</b>
Current	14 ± 5.00	216 ± 10.29	
≥3 alcoholic drinks per day			
Yes	1 ± 0.35	18 ± 0.85	
No	288 ± 99.65	2110 ± 99.15	0.72
Rheumatoid arthritis, No. (%)			
Yes	30 (10.38)	154 (7.24)	
No	259 (89.62)	1974 (92.76)	0.06
Previous fragility fractures, No. (%)			
Yes	114 (39.45)	528 (24.81)	
No	175 (60.55)	1600 (75.19)	<b>&lt;.0001</b>
Familial history of hip fracture, No. (%)			
Yes	40 (13.84)	177 (8.32)	
No	249 (86.16)	1951 (91.68)	<b>0.002</b>
PGS, mean (SD)	2.27 ± 0.22	2.27 ± 0.23	0.81
T-score, mean (SD)	-1.36 ± 1.11	-0.72 ± 1.16	<b>&lt;.0001</b>
Follow up days (SD)	1967.19 ± 1457.08	5075.27 ± 2144.22	<b>&lt;.0001</b>


182 *PGS: polygenic score calculated based on 63 BMD-related SNPs. Significant results are in boldface.*

183

### 184 3.2. Performance of T-score in predicting MOF and any fracture

185 The T-score prediction versus observed cumulative incidence of MOF and any fracture during  
186 the 19-year follow-up period by PGS groups are shown in **Figure 1A**. The 19-year MOF incidence  
187 derived from T-score significantly underestimated risk across all PGS groups. The most significant  
188 underestimation by T-score was observed in women who had low PGS, in which the cumulative  
189 incidence of MOF was 3.83% versus observed 8.8%, with a corresponding predicted/observed ratio  
190 (POR) of 0.43 (95% CI, 0.28-0.64), followed by the medium PGS group with a POR of 0.71 (95% CI,  
191 0.56-0.90); and in the high PGS group, the POR was 0.72 (95% CI, 0.52-0.98). Similar results were  
192 also observed when using any fracture as the outcome, the estimated incidence calculated by T-  
193 score underestimated fracture risk in all PGS groups (**Figure 1B**).

194 **Figure 1.** Observed versus predicted major osteoporotic fracture (A) and any fracture (B) probability  
 195 stratified by polygenic score group. The dotted line indicates a relative ratio of 1 (reference line); ratio < 1  
 196 indicates that T-score underestimates fracture risk.  
 197



198

(A)

(B)

199

200

201 The predicted versus observed cumulative incidence of MOF and any fracture by racial  
 202 groups are shown in **Figure 2**. The T-score estimated incidence of MOF underestimated fracture  
 203 risk in all racial groups except American Indians, with the statistically significant  
 204 underestimation only observed in African American and Caucasian women. In African  
 205 American women, the predicted incidence of MOF was 1.42% versus observed 2.73%, and the  
 206 POR was 0.52 (95% CI 0.30-0.83). In Caucasian women, the predicted incidence of MOF was  
 207 11.55%, as opposed to observed 18.38%, with the POR being 0.63 (95% CI 0.50-0.78) (**Figure 2A**).  
 208 Similarly in any fracture, significant underestimation of the fracture incidence was observed in  
 209 African American (POR: 0.19, 95% CI: 0.11-0.31), Hispanic (POR: 0.48, 95% CI: 0.33-0.67), and  
 210 Caucasian women (POR: 0.47, 95% CI: 0.37-0.59) (**Figure 2B**)

211

212

213

214

215

216

217

218

219

220

221

222


223

224

225

226  
227  
228  
229

**Figure 2.** Observed versus predicted major osteoporotic fracture (A) and any fracture (B) probability stratified by race. The dotted line indicates a relative ratio of 1 (reference line), ratio < 1 indicates that T-score underestimates fracture risk.




231

**Figure 3** demonstrates the false positive rate and false-negative rate for MOF and any fracture based on the T-score classification by the PGS group. By defining a T-score < -2.5 as the presence of osteoporosis, for MOF prediction, the false positive rate of this test was low across all PGS groups, with the lowest sensitivity of T-score observed among women who have low genetic risk of low bone mass (3.58%). The false-negative rate was highest in the low PGS group (92.86%), followed by the high PGS group (85.42%), and medium PGS group (80.95%). Similar results were also observed in the outcome of any fracture.


239  
240

**Figure 3.** False-positive rate and false-negative rate for major osteoporotic fracture and any fracture in the analytic sample by polygenic score group.



241 **Figure 4** demonstrates the race-specific false positive rate and false-negative rate for  
 242 MOF and any fracture based on the T-score classification. By defining a T-score < -2.5 as the  
 243 presence of osteoporosis, for MOF prediction, the false positive rate of this test was low across  
 244 all race groups, with the lowest observed among African American women (1.35%), followed by  
 245 Hispanic women (5.07%), American Indian women (6.6%), and Caucasians (9.8%). The false-  
 246 negative rate was high across all race groups, with the lowest observed in Caucasians (79.44%)  
 247 and the highest in African Americans (96.15%). Similar results were also observed for the  
 248 outcome of any fractures.

249 **Figure 4.** False-positive rate and false-negative rate for major osteoporotic fracture and any fracture  
 250 in the analytic sample by race.



251 3.3. PGS and the fracture outcome

252 In the cox proportional hazard model, after adjusting for baseline T-score classification,  
 253 weighted PGS calculated from 63 femoral neck BMD-related SNPs was not significantly associated  
 254 with subsequent MOF. Compared to the low PGS group, the probability of sustaining a MOF was  
 255 14% lower for women with medium genetic risk (HR=0.86, 95% CI 0.68-1.09) and 2% lower for  
 256 women with high genetic risk (HR=0.98, 95% CI 0.75-1.28). Similar findings with outcome of any  
 257 fracture were observed (**Table 2**).

258 **Table 2.** Hazard Ratios (HR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture  
 259 According to polygenic score group, adjusted for T-score diagnosis, and race: results from the Cox  
 260 Proportional Hazard Model.

	Major osteoporotic fracture	Any fracture
	HR (95 % CI)	HR (95 % CI)
Adjusted for T-score diagnosis		
low	1(reference)	1(reference)
medium	0.86 (0.68-1.09)	0.81 (0.65-1.00)
high	0.98 (0.75-1.28)	0.89 (0.70-1.13)

261 *Significant results are in boldface.*

262 3.4. Race/ethnicity and the fracture outcome

263 After controlling for baseline T-score, race remained a significant predictor of subsequent  
 264 MOF and any fracture. Compared to Caucasian women, African American women had a 59%  
 265 lower hazard of MOF (HR=0.41, 95% CI 0.33-0.52) and 47% lower hazard of any fracture  
 266 (HR=0.43, 95% CI 0.32-0.88); American Indian women had a 41% lower hazard of MOF (HR=0.59,  
 267 95% CI 0.35-0.99) and 56% lower hazard of any fracture (HR=0.44, 95% CI 0.36-0.54); Hispanic  
 268 women had a 55% lower risk of MOF (HR=0.55, 95% CI 0.35-0.58) and 54% lower risk of any  
 269 fracture (HR=0.46, 95% CI 0.36-0.58). The potential impact of PGS on the estimated risk of MOF  
 270 and any fractures across different racial groups was also assessed. When adjusted for T-score  
 271 and PGS group, the impact of race on the estimated probabilities MOF and hip fracture was  
 272 slightly attenuated but remained statistically significant. Similar results were observed when  
 273 using any fractures as the outcome (**Table 3**).

274 **Table 3.** Hazard Ratios (HR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture  
 275 According to race group, adjusted for T-score diagnosis, and polygenic score groups: results from cox  
 276 proportional hazard model.

	Major osteoporotic fracture	Any fracture
	OR (95 % CI)	OR (95 % CI)
Adjusted for T-score diagnosis		
Caucasian	1(reference)	1(reference)
American Indian	<b>0.59 (0.35-0.99)</b>	<b>0.53 (0.32-0.88)</b>
African American	<b>0.41 (0.33-0.52)</b>	<b>0.44 (0.36-0.54)</b>
Hispanic	<b>0.45 (0.35-0.58)</b>	<b>0.46 (0.36-0.58)</b>
Adjusted for T-score diagnosis + PGS		
Caucasian	1(reference)	1(reference)
American Indian	<b>0.56 (0.33-0.97)</b>	<b>0.52 (0.31-0.87)</b>
African American	<b>0.41 (0.33-0.52)</b>	<b>0.44 (0.35-0.54)</b>
Hispanic	<b>0.44 (0.34-0.58)</b>	<b>0.46 (0.36-0.59)</b>

277 PGS: polygenic score calculated based on 63 bone mineral density-related SNPs. Significant results are in boldface.

278

279 3.4. Sensitivity analysis

280 We conducted a sensitivity analysis in which subjects who had previous fracture at baseline  
 281 were excluded. Results of the Cox Proportional Hazard Model remained the same except that after  
 282 adjustment for T-score diagnosis and PGS, the impact of race on the estimated risk of MOF and any  
 283 fractures attenuated slightly. Compare to Caucasian women, the adjusted hazard of MOF was 43%,  
 284 and 55% lower in African-American and Hispanic women, respectively. The hazard of MOF was no  
 285 longer significant between Caucasian and American Indian women. Similar results were also  
 286 observed when using any fracture as the outcome (**Supplementary Table 1&2**).

287 4. Discussion

288 The present study provides compelling evidence that the T-score method underestimates the  
 289 risk of MOF and any fracture in women 50-79 years old, across all racial and PGS groups, especially  
 290 in African Americans and women who have low genetic risk. Moreover, the prognostic  
 291 performance of the T-score method estimated by false-positive rate and false-negative rate using the  
 292 cut-off value of -2.5 differed across race and PGS groups as well. Results from the multivariate Cox

293 Proportional Models provided further evidence that the performance of the T-score method in  
294 predicting osteoporotic fracture risks varies by race.

295 The BMD threshold defined by the WHO T-score method was found to be problematic. The  
296 National Osteoporosis Risk Assessment Study found that 82% of 2,259 women who reported  
297 fractures had a T-score  $> -2.5$  [22]. Similarly, in the Rotterdam Study of 7,806 people, both 56% of  
298 women and 79% of men with non-vertebral fractures had a T-score of  $> -2.5$  [23]. Other studies also  
299 demonstrated that the majority of low-trauma fractures occur in individuals whose T-scores were  
300 above  $-2.5$  [24,25], which is consistent with the extremely high false-negative rates observed in the  
301 present study, especially in African American and Hispanic women, as well as women who have  
302 low genetic risk. However, the percentage of being misclassified into a high-risk group without  
303 sustaining a fracture is highest among Caucasian women when a T-score method is used to assess  
304 fracture risk. BMD is known to be the single best predictor of fracture and the differences have been  
305 identified in the areal BMD between ethnic and racial groups [26]. However, the observed  
306 cumulative incidence of fracture, in terms of both MOF and any fracture, was significantly higher  
307 than the estimation derived from the BMD-based T-score method in minorities. The results of  
308 multivariate Cox Proportional Hazard Analysis further demonstrated that race is a significant  
309 predictor of MOF and any fracture independent of the T-score classification. Although separate  
310 reference database was proposed for Africa Americans and Hispanics [27], we did not use this  
311 ethnic-specific references in this study because whether the T-score derived from the ethnic-specific  
312 database performs better or worse in osteoporosis diagnosis remains unclear [28]. Nonetheless, our  
313 previous study suggested that a new classification method of low BMD based on the race-specific  
314 lower limit of normal values may help mitigate some of the T-score limitations in minority  
315 populations [29].

316 The present study found that T-score greatly underestimated the risk of fracture in women  
317 aged 50-79 years, and the degree of underestimation by the T-score method in the low PGS group is  
318 greater than in the high genetic risk groups in both outcomes of MOF and any fracture. However, in  
319 the multivariate analysis, genetic profiling was demonstrated not to be a significant predictor of  
320 MOF and any fracture, after T-score classification was adjusted for. Prior twin studies demonstrated  
321 that the heritable component of fracture is largely independent of BMD [30,31], whereas the  
322 reported fracture-related genetic variants are also associated with BMD [32]. Due to the study  
323 power issue, GWAS for dichotomous disease as a direct outcome has yielded relatively lower  
324 numbers of loci discovered, and this is also the concern for osteoporotic fracture studies as well.  
325 Moreover, the multifactorial nature of fracture is another issue that makes it challenging to identify  
326 the specific genetic determinants that contribute to the risk of fractures. Therefore, the PGS  
327 constructed in the present study may not sufficiently capture the BMD-independent genetic risk of  
328 fracture. With more fracture-related genetic components being discovered, a more significant effect  
329 of PGS on fracture risk prediction should be foreseen. Another possible reason for the minor effect  
330 of PGS on fracture outcomes observed in the present study is that, similar to other age-related traits,  
331 the heritability of fracture risk decreases with age [32]. Since the analytic sample consisted of older  
332 women, the effect mediated through genetic influences on bone turnover, and bone geometry or  
333 non-skeletal factors such as cognitive function, neuromuscular control, visual acuity, or other  
334 factors related to the risk of falling might be more attributable to the predisposition of fracture [33].

335 Limitations to this study are acknowledged. First, the WHI data we used only included women  
336 50-79 years, so our findings may not apply to men or to women who are not in the age range of this  
337 study. Second, genetic variants related to fracture risk independent of BMD remain mostly  
338 undiscovered and likely most related genetic variants have not been included in the present study.  
339 Therefore they had a limited impact on the T-score classification. Thirdly, concerning the allele  
340 frequencies, osteoporotic fracture risk is associated with common and rare variants. Since all SNPs  
341 used in the current study were based on a prior GWAS meta-analysis, which likely be able to  
342 discover only common genetic variants, the BMD or fracture-related rare genetic determinants may

343 not be included. Finally, the sample size of minority subjects was very small in this study; the  
344 results may, therefore, be underpowered.

## 345 5. Conclusions

346 To the best of our knowledge, this is the first study to assess T-score performance in the  
347 prediction of MOF and any fractures in groups with different genetic profiling and of various races.  
348 Our findings demonstrated that T-score performed differently in different races and PGS groups, and  
349 thus the effect of race and genetic determinants in osteoporotic fracture prediction should be taken  
350 into account beyond the T-score classification. Fully integrating genetic profiling and racial factors  
351 into the existing fracture assessment model is very likely to improve the accuracy of osteoporosis  
352 diagnosis. Thus, developing racial/ethnic-specific, individualized osteoporosis diagnosis methods  
353 will provide more accurate fracture risk assessment and decrease false-positive rate and false-  
354 negative rates of osteoporosis diagnosis. Further studies, especially these including men, more  
355 extensive sample of minorities, and more comprehensive fracture-associated genetic variants, are  
356 warranted.

357

358 **Supplementary Materials:** The following are available online at [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Table S1: Hazard  
359 Ratios (HR) with 95% Confidence Interval (CI) for Outcomes of Incidence Fracture According to Race Group,  
360 adjusted for T-score diagnosis, age, BMI, previous fracture and PGS groups: results from Cox Proportional  
361 Hazard Model, individuals with previous fractures were excluded; Table S2: Hazard Ratios (HR) with 95%  
362 Confidence Interval (CI) for Outcomes of Incidence Fracture According to race group, adjusted for T-score  
363 diagnosis, age, BMI, previous fracture and PGS groups: results from cox proportional hazard model, individuals  
364 with previous fractures were excluded.

365 **Author Contributions:** conceptualization, Q.W.; methodology, Q.W., X.X. and Y.X.; software, Y.X.; validation,  
366 Q.W., X.X. and Y.X.; formal analysis, Y.X.; investigation, Q.W., X.X. and Y.X.; resources, Q.W.; data curation, X.X.  
367 and Y.X.; writing—original draft preparation, Q.W., X.X.; writing—review and editing, Q.W. X.X. and Y.X.;  
368 visualization, X.X. and Y.X.; supervision, Q.W.; project administration, Q.W.; funding acquisition, Q.W.

369 **Funding:** This research was funded by a grant from the National Institute of General Medical Sciences (P20GM121325),  
370 a grant from the National Institute on Minority Health and Health Disparities of the National Institutes of Health  
371 (R15MD010475).

372 **Acknowledgments:** The data/analyses presented in the current publication are based on the use of study data  
373 downloaded from the dbGaP web site, under phs000200 ([https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study\\_id=phs000200.v12.p3](https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000200.v12.p3)). The Genome Acquisition to Analytics (GAA) Research Core of the  
374 Personalized Medicine Center of Biomedical Research Excellence in the Nevada Institute of Personalized  
375 Medicine and the National Supercomputing Institute at the University of Nevada Las Vegas provided facilities  
376 for bioinformatics analysis in this study. The funding sponsors were not involved in the analysis design,  
377 genotype imputation, data analysis, interpretation of the analysis results, or the preparation, review, or approval  
378 of this manuscript.  
379

380 **Conflicts of Interest:** The authors declare no conflict of interest.

381

382

383

384

385

386

387 **References**

- 388 1. National Clinical Guideline, C. National Institute for Health and Clinical Excellence: Guidance. In *Osteoporosis:*  
389 *Fragility Fracture Risk: Osteoporosis: Assessing the Risk of Fragility Fracture*, Royal College of Physicians (UK),  
390 National Clinical Guideline Centre.: London, 2012.
- 391 2. Compston, J. Osteoporosis: social and economic impact. *Radiologic clinics of North America* **2010**, *48*, 477-482,  
392 doi:10.1016/j.rcl.2010.02.010.
- 393 3. Jeremiah, M.P.; Unwin, B.K.; Greenawald, M.H.; Casiano, V.E. Diagnosis and Management of Osteoporosis.  
394 *American family physician* **2015**, *92*, 261-268.
- 395 4. Sozen, T.; Ozisik, L.; Basaran, N.C. An overview and management of osteoporosis. *European journal of rheumatology*  
396 **2017**, *4*, 46-56, doi:10.5152/eurjrheum.2016.048.
- 397 5. Lips, P. Epidemiology and predictors of fractures associated with osteoporosis. *The American Journal of Medicine*  
398 **1997**, *103*, S3-S11, doi:10.1016/S0002-9343(97)90021-8.
- 399 6. Kanis, J.A.; Borgstrom, F.; De Laet, C.; Johansson, H.; Johnell, O.; Jonsson, B.; Oden, A.; Zethraeus, N.; Pflieger, B.;  
400 Khaltaev, N. Assessment of fracture risk. *Osteoporosis international : a journal established as result of cooperation*  
401 *between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* **2005**, *16*, 581-589,  
402 doi:10.1007/s00198-004-1780-5.
- 403 7. Cosman, F.; de Beur, S.J.; LeBoff, M.S.; Lewiecki, E.M.; Tanner, B.; Randall, S.; Lindsay, R. Clinician's Guide to  
404 Prevention and Treatment of Osteoporosis. *Osteoporosis international : a journal established as result of cooperation*  
405 *between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* **2014**, *25*, 2359-  
406 2381, doi:10.1007/s00198-014-2794-2.
- 407 8. Roux, S.; Cabana, F.; Carrier, N.; Beaulieu, M.; April, P.-M.; Beaulieu, M.-C.; Boire, G. The World Health  
408 Organization Fracture Risk Assessment Tool (FRAX) Underestimates Incident and Recurrent Fractures in  
409 Consecutive Patients With Fragility Fractures. *The Journal of Clinical Endocrinology & Metabolism* **2014**, *99*, 2400-2408,  
410 doi:10.1210/jc.2013-4507.
- 411 9. Crandall, C.J.; Schousboe, J.T.; Morin, S.N.; Lix, L.M.; Leslie, W. Performance of FRAX and FRAX-Based Treatment  
412 Thresholds in Women Aged 40 Years and Older: The Manitoba BMD Registry. *Journal of bone and mineral research :  
413 the official journal of the American Society for Bone and Mineral Research* **2019**, *34*, 1419-1427, doi:10.1002/jbmr.3717.
- 414 10. Ettinger, B.; Ensrud, K.E.; Blackwell, T.; Curtis, J.R.; Lapidus, J.A.; Orwoll, E.S.; Group, F.t.O.F.i.M.S.R.  
415 Performance of FRAX in a cohort of community-dwelling, ambulatory older men: the Osteoporotic Fractures in  
416 Men (MrOS) study. *Osteoporosis International* **2013**, *24*, 1185-1193, doi:10.1007/s00198-012-2215-3.
- 417 11. Leslie, W.D.; Morin, S.N.; Lix, L.M.; Niraula, S.; McCloskey, E.V.; Johansson, H.; Harvey, N.C.; Kanis, J.A.  
418 Performance of FRAX in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based  
419 Cohort Study. *Journal of Bone and Mineral Research* **2019**, *34*, 1428-1435, doi:10.1002/jbmr.3726.
- 420 12. Unnanuntana, A.; Gladnick, B.P.; Donnelly, E.; Lane, J.M. The assessment of fracture risk. *J Bone Joint Surg Am*  
421 **2010**, *92*, 743-753, doi:10.2106/JBJSI.00919.
- 422 13. Melton, L.J., 3rd. History of the Rochester Epidemiology Project. *Mayo Clinic proceedings* **1996**, *71*, 266-274,  
423 doi:10.4065/71.3.266.
- 424 14. World Health, O. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis :  
425 report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. World Health Organization:  
426 Geneva, 1994.
- 427 15. Pennes, D.R. T-Score Determination in Bone Densitometry. *American Journal of Roentgenology* **2011**, *197*, W1166-  
428 W1166, doi:10.2214/AJR.11.7063.

- 429 16. Hans, D.; Downs, R.W.; Duboeuf, F.; Greenspan, S.; Jankowski, L.G.; Kiebzak, G.M.; Petak, S.M. Skeletal Sites for  
430 Osteoporosis Diagnosis: The 2005 ISCD Official Positions. *Journal of Clinical Densitometry* **2006**, *9*, 15-21,  
431 doi:<https://doi.org/10.1016/j.jocd.2006.05.003>.
- 432 17. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative  
433 Study Group. *Controlled clinical trials* **1998**, *19*, 61-109, doi:10.1016/s0197-2456(97)00078-0.
- 434 18. Jackson, R.D.; LaCroix, A.Z.; Gass, M.; Wallace, R.B.; Robbins, J.; Lewis, C.E.; Bassford, T.; Beresford, S.A.; Black,  
435 H.R.; Blanchette, P., et al. Calcium plus vitamin D supplementation and the risk of fractures. *The New England*  
436 *journal of medicine* **2006**, *354*, 669-683, doi:10.1056/NEJMoa055218.
- 437 19. Watts, N.B.; Leslie, W.D.; Foldes, A.J.; Miller, P.D. 2013 International Society for Clinical Densitometry Position  
438 Development Conference: Task Force on Normative Databases. *Journal of clinical densitometry : the official journal of*  
439 *the International Society for Clinical Densitometry* **2013**, *16*, 472-481, doi:10.1016/j.jocd.2013.08.001.
- 440 20. Chen, Z.; Kooperberg, C.; Pettinger, M.B.; Bassford, T.; Cauley, J.A.; LaCroix, A.Z.; Lewis, C.E.; Kipersztok, S.;  
441 Borne, C.; Jackson, R.D. Validity of self-report for fractures among a multiethnic cohort of postmenopausal  
442 women: results from the Women's Health Initiative observational study and clinical trials. *Menopause (New York,*  
443 *N.Y.)* **2004**, *11*, 264-274, doi:10.1097/01.gme.0000094210.15096.fd.
- 444 21. Estrada, K.; Styrkarsdottir, U.; Evangelou, E.; Hsu, Y.-H.; Duncan, E.L.; Ntzani, E.E.; Oei, L.; Albagha, O.M.E.;  
445 Amin, N.; Kemp, J.P., et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci  
446 associated with risk of fracture. *Nat Genet* **2012**, *44*, 491-501, doi:10.1038/ng.2249.
- 447 22. Siris, E.S.; Chen, Y.T.; Abbott, T.A.; Barrett-Connor, E.; Miller, P.D.; Wehren, L.E.; Berger, M.L. Bone mineral  
448 density thresholds for pharmacological intervention to prevent fractures. *Archives of internal medicine* **2004**, *164*,  
449 1108-1112, doi:10.1001/archinte.164.10.1108.
- 450 23. Schuit, S.C.; van der Klift, M.; Weel, A.E.; de Laet, C.E.; Burger, H.; Seeman, E.; Hofman, A.; Uitterlinden, A.G.; van  
451 Leeuwen, J.P.; Pols, H.A. Fracture incidence and association with bone mineral density in elderly men and women:  
452 the Rotterdam Study. *Bone* **2004**, *34*, 195-202, doi:10.1016/j.bone.2003.10.001.
- 453 24. Kanis, J.A.; McCloskey, E.V.; Johansson, H.; Cooper, C.; Rizzoli, R.; Reginster, J.Y. European guidance for the  
454 diagnosis and management of osteoporosis in postmenopausal women. *Osteoporosis international : a journal*  
455 *established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis*  
456 *Foundation of the USA* **2013**, *24*, 23-57, doi:10.1007/s00198-012-2074-y.
- 457 25. Lespessailles, E.; Cortet, B.; Legrand, E.; Guggenbuhl, P.; Roux, C. Low-trauma fractures without osteoporosis.  
458 *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis*  
459 *and the National Osteoporosis Foundation of the USA* **2017**, *28*, 1771-1778, doi:10.1007/s00198-017-3921-7.
- 460 26. Leslie, W.D. Ethnic Differences in Bone Mass—Clinical Implications. *The Journal of Clinical Endocrinology &*  
461 *Metabolism* **2012**, *97*, 4329-4340, doi:10.1210/jc.2012-2863.
- 462 27. Looker, A.C.; Wahner, H.W.; Dunn, W.L.; Calvo, M.S.; Harris, T.B.; Heyse, S.P.; Johnston, C.C., Jr.; Lindsay, R.  
463 Updated data on proximal femur bone mineral levels of US adults. *Osteoporosis international : a journal established as*  
464 *result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the*  
465 *USA* **1998**, *8*, 468-489, doi:10.1007/s001980050093.
- 466 28. Walker, M.D.; Bilezikian, J.P. Racial differences in bone density and fracture risk in the United States. *International*  
467 *Journal of Rheumatic Diseases* **2008**, *11*, 341-346, doi:10.1111/j.1756-185X.2008.00390.x.
- 468 29. Wu, Q.; Lefante, J.J.; Rice, J.C.; Magnus, J.H. Age, race, weight, and gender impact normative values of bone  
469 mineral density. *Gender medicine* **2011**, *8*, 189-201, doi:10.1016/j.genm.2011.04.004.
- 470 30. Andrew, T.; Antoniadou, L.; Scurrah, K.J.; Macgregor, A.J.; Spector, T.D. Risk of wrist fracture in women is  
471 heritable and is influenced by genes that are largely independent of those influencing BMD. *Journal of bone and*

- 472 *mineral research : the official journal of the American Society for Bone and Mineral Research* **2005**, *20*, 67-74,  
473 doi:10.1359/jbmr.041015.
- 474 31. Ralston, S.H.; Uitterlinden, A.G. Genetics of osteoporosis. *Endocrine reviews* **2010**, *31*, 629-662, doi:10.1210/er.2009-  
475 0044.
- 476 32. Koromani, F.; Trajanoska, K.; Rivadeneira, F.; Oei, L. Recent Advances in the Genetics of Fractures in Osteoporosis.  
477 *Front Endocrinol (Lausanne)* **2019**, *10*, 337-337, doi:10.3389/fendo.2019.00337.
- 478 33. Ralston, S.H.; de Crombrughe, B. Genetic regulation of bone mass and susceptibility to osteoporosis. *Genes &*  
479 *development* **2006**, *20*, 2492-2506, doi:10.1101/gad.1449506.
- 480